Page last updated: 2024-08-25

rosiglitazone and Angor Pectoris

rosiglitazone has been researched along with Angor Pectoris in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Alméras, N; Angel, J; Batalla, N; Bertrand, OF; Costerousse, O; De Larochellière, R; Després, JP; Dzavik, V; Natarajan, M; Poirier, P; Rinfret, S; Rodés-Cabau, J; Roy, L; Title, L	1
Chang, YW; Chen, WL; Chou, CC; Kao, TW; Loh, CH; Wang, CC	1

Trials

1 trial(s) available for rosiglitazone and Angor Pectoris

Article	Year
A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the VeIn-Coron The Canadian journal of cardiology, 2009, Volume: 25, Issue:9 Topics: Adult; Aged; Angina Pectoris; Atherosclerosis; Blood Glucose; Coronary Artery Bypass; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Middle Aged; Postoperative Complications; Prospective Studies; Quebec; Rosiglitazone; Spain; Thiazolidinediones; Treatment Outcome; Vasodilator Agents	2009

Article

Year

A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the VeIn-Coron

The Canadian journal of cardiology, 2009, Volume: 25, Issue:9

Topics: Adult; Aged; Angina Pectoris; Atherosclerosis; Blood Glucose; Coronary Artery Bypass; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Middle Aged; Postoperative Complications; Prospective Studies; Quebec; Rosiglitazone; Spain; Thiazolidinediones; Treatment Outcome; Vasodilator Agents

2009

Other Studies

1 other study(ies) available for rosiglitazone and Angor Pectoris

Article	Year
Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population. Clinical therapeutics, 2011, Volume: 33, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Antihypertensive Agents; Cardiovascular Diseases; Cerebrovascular Disorders; Chi-Square Distribution; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Incidence; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Pioglitazone; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Rosiglitazone; Taiwan; Thiazolidinediones; Time Factors; Treatment Outcome	2011

Article

Year

Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.

Clinical therapeutics, 2011, Volume: 33, Issue:12

Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Antihypertensive Agents; Cardiovascular Diseases; Cerebrovascular Disorders; Chi-Square Distribution; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Incidence; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Pioglitazone; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Rosiglitazone; Taiwan; Thiazolidinediones; Time Factors; Treatment Outcome

2011